Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
Microneedles technology for covid-19 vaccine
Emergex have inclusivity to use Midatech Pharma microneedles tech
Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine
5th January 2021/
Agreement provides a framework for future clinical trials, manufacturing, sales and marketing, and distribution within the National Health Service of Brazil
Bio-Manguinhos, is a world leader in vaccine development and manufacturing and one of the productive units of Fiocruz, one of the world’s most respected public health research
institutions
Abingdon, Oxon, UK, 5 January 2021 – Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global infectious disease threats through the development of synthetic ‘set point’ vaccines which prime the T-Cell immune response, today announces that it has signed a collaboration and development agreement with the Institute of Technology on Immunobiologicals (Bio-Manguinhos) of the Oswaldo Cruz Foundation (Fiocruz) in Brazil to develop a COVID-19 vaccine using Emergex’s next generation synthetic T-Cell vaccine technology.
The agreement provides a framework under which both parties will work together to progress certain immunotherapeutic programmes, including a vaccine candidate for COVID-19, through a regulatory pathway for the Brazilian National Health Service. Emergex will also support the performance of studies, including clinical trials, and to manufacture, market, promote and distribute certain infectious diseases vaccines within the National Health Service of Brazil.
Emergex has already completed preclinical development work including toxicology and immunoproteomic research into the MHC Class I peptide expression library for cell surface expressed peptides on SARS-Cov-2 infected cells, which define the repertoire of an effective T-Cell immune response to the COVID-19 disease.
In August 2020, a previous research collaboration between Emergex and Bio-Manguinhos / Fiocruz resulted in the determination of the MHC CD8 T-Cell epitope expression library for Fiocruz’s commercial yellow fever vaccine.
Bio-Manguinhos / Fiocruz and Emergex will share initial set up and development costs. Further financial details have not been disclosed.
Have you seen this?
Emergex Vaccines Raises US$11 million to Advance Pipeline of Synthetic T-Cell Vaccines for Infectious Diseases
18th November 2020/
Investor support further endorsement of vaccine development strategy
Novel approach to vaccine development could address urgent global need for safe,
effective vaccines that can be rapidly developed and deployed
Abingdon, Oxon, UK, 18 November 2020 – Emergex Vaccines Holding Limited (‘Emergex’), a company tackling major global infectious disease threats through the development of synthetic ‘set point’ vaccines which prime the T-cell immune response, today announces that it has raised $11 million in a funding round supported by new and existing investors. This round follows a successful $11 million Series A completed in January 2020.
The proceeds of this funding round will, among other things, enable Emergex to further advance and execute its vaccine development strategy, producing vaccine candidates for some of the world’s most threatening and virulent diseases such as COVID-19, Dengue Fever and pandemic flu.
Emergex’s next generation vaccines have been designed to expand the body’s natural immune response by programing CD8+ T-cells to rapidly recognise and respond to pathogens. This approach is aimed at providing effective prevention of disease while eliminating the allergic, autoimmune or antibody mediated side effects associated with traditional vaccines. Emergex’s vaccines are 100% synthetic – requiring no biology for manufacturing – thus having the potential to be rapidly produced and cost-effectively scaled. They are delivered through a microneedle system which allows for convenient administration and require no cold chain in storage or distribution
Sky News has learnt that EQT Infrastructure tabled an offer thought to have been worth roughly $3.7bn for First Student and First Transit just days before Christmas
£1Billion Market Cap Target #ArgoBlockchain
#ARB 350-370p
$ARBKF $4.5-5
#Bitcoin #BTC
#ArgoBlockchain the most undervalued #BITCOIN miner on the planet https://t.co/zhYP7DKZbl
Hawkwing is seeking to acquire one or more companies in the technology sector that provide solutions for specific industries such as digital marketing, medical applications, business and financial services and the sports sector
Hydrogen boiler anyone
Interesting response
https://twitter.com/Tom08154584/status/1341737814610882564?s=19
Over 100% back to nominal 10p hmmm
OilManJim on twatter
He know his siht about oil and gas industry, but absolutely useless with market mechanics.
UJO paid ~$1.5/boe for their West Newton stake with 1 well drilled and gas confirmed
What did Reabold pay for their stake? Guessing similar
So they punched one more well and barrel in the ground is suddenly worth $10 lol
Good luck all
I would personally flow this sidetrack first and bump the flowrates until the reading is maxed out to maximum allowed flowrate and then announce this so rhat share price zooms
Uggy100,
Yes and under $3/bbl
Read COPL Atomic acquisition
They are paying $54M for 31.1mmboe 2P Proved and Probable Reserves, oil is already producing.
Talking about $3/bbl for West Newton is crazy.
Three wells drilled and no Reserves booked due to no commercial flowrates established meh...
What you have is 350-500mmboe OIIP, 2C figure will probably be 200mmboe tops, 2C ballpark is $1/bbl
2P Reserves in confirmed development with a full planning permission for 20years 4-5/bbl
See what UJO paid for Wressle, will give you pretty good and correct guidance...
Lunatics talking about $10/barrel for the asset which doesn't have a full planning permission, no commercial flowrates confirmed, no liquid content confirmed, no gas content confirmed, no field development plan...
$2billion for West Newton then lol
And Brent is $52 not over $70 where you can have plenty margin left for workovers and additional producers drilled.
Wrong assumption
Two primary targets, Albian and Aptian, dead oil shows in Albian and live oil shows in Aptian reported(DST's two zones in Aptian at Doubloon Saxon well) in the nearby wells.
Aptian horizons are more important than Albian which they should hit in around 12days time from today.
Perseverance-1 is at structural high/updip.
TD will be confirmed when the drill progresses.
Good fortunes all
And mind the leaks 1st week of Jan, will be amazed if they read oil gusher in Albian, 11% COS or upgraded 25% COS
Aptian 14% COS or upgraded 34% COS and according to chief BPC cook it is amazing.
My personal BPC Target if they confirm the oil discovery and sizeable at that then 12-15p isy nearterm exit target
Duster and 0.5p target
Manage your risks and don't lose your head in the bullkak
This is frontier exploration and extreme caution and well calculated risks need to be applied.
Appologies
Yes 36" conductor is ~75m
Water depth 1689ft/514.8m
36" conductor set at 1936ft/590m
(EIA Doc page 24) Fig 2-10 Schematic
Thanks CoMan
Might be wrong here...
Spudding offshore would mean when the drillbit hits the seafloor so upto 2days from drillship arrival in that case.
Apologies for the mix up
Thanks bynari
From EIA doc page 16 Proppsed schedule for well drilling
Prepare to drill 1day
36" casing
Jet the 36" casing to 600m 2days
20" casing 4days
Drill 26" hole to 1000m
Rund 20" casing and cement
Run BOP on the riser
1+2+4=7
7days to spud from drillship arrival at location.
So if arrival on 19Dec then spud and rns on 26Dec
SharkMoomin,
EIA doc states there will be no flowtesting.
So all good and greenies are cool with that.
Pageofcups,
Are you sure they are allowed to perform DST???
Could you please point me to the right doc where DST and flowtest is mentioned?
From what I read they are not testing the well